CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the decision to discontinue the ORION program of AMX0035 (sodium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback